Shanghai Abelzeta Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Shanghai Cellular Biopharmaceutical Group Ltd. (to 2024)
1
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 19, 2027The maintenance fee for Method for Large-Scale Production of Lentivirus by Using Gmp-Level Serum-Free Suspension Cells (US 11,845,962) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,375,211 | Method for detection and quantification of T-cell receptor Vβ repertoire In force · From the USPTO record | In force | From the USPTO record | |
| US 12,180,513 | Method for Large-Scale Production of Lentivirus by Using Gmp-Level Serum-Free Suspension Cells In force · High confidence | In force | High confidence | |
| US 11,142,581 | Bcma-Targeted Chimeric Antigen Receptor as Well as Preparation Method Therefor and Application Thereof In force · High confidence | In force | High confidence | |
| US 11,498,973 | BCMA-Targeted Chimeric Antigen Receptor as well as Preparation Method Therefor and Application Thereof In force · High confidence | In force | High confidence | |
| US 12,637,516 | BCMA-Targeted Chimeric Antigen Receptor as well as Preparation Method Therefor and Application Thereof In force · High confidence | In force | High confidence | |
| US 11,845,962 | Method for Large-Scale Production of Lentivirus by Using Gmp-Level Serum-Free Suspension Cells In force · High confidence | In force | High confidence | |
| US 12,577,614 | Kits and Methods for Determining Copy Number of Mouse TCR Gene In force · High confidence | In force | High confidence | |
| US 12,673,071 | Anti-Bcma Antibodies and Chimeric Antigen Receptors In force · High confidence | In force | High confidence | |
| US 12,674,136 | Methods for Preparing Tumor-Infiltrating Lymphocytes In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending